Skip to main content

Test Price

800 AED

✅ Home Collection Available

Sickle Cell Anemia Mutation Detection Test in UAE | 800 AED | DHA-Licensed Molecular Diagnostic

Executive Summary & Core Metrics

This advanced molecular genetic assay provides definitive detection of pathogenic HBB gene mutations responsible for sickle cell disease using PCR amplification and Sanger DNA sequencing, achieving 99.9% diagnostic sensitivity. Offered by DNA Labs UAE under DHA Facility License 1143, the test delivers unambiguous genotype confirmation essential for prenatal counseling, premarital screening compliance, and personalized disease management. Results are interpreted by Consultant Medical Genetics specialist Lina Osama Zaki Quteineh (DHA Registration ID: 9294403), with post-test telephonic consultation included.

Accuracy Guarantee 99.9% Diagnostic Sensitivity ISO 9001:2015 Accredited Processing
Premium Logistics VIP Mobile Phlebotomy Temperature-Controlled Cold-Chain Home Collection — Available Daily 8 AM to 11 PM
Clinical Guidance Post-Test Telephonic Consultation Expert Result Interpretation by Consultant Medical Genetics
Insurance Support Direct Billing Verification WhatsApp: +971 54 548 8731

Test Overview & Methodology

The Sickle Cell Anemia Mutation Detection Test is a definitive molecular diagnostic assay that identifies pathogenic variants in the HBB gene (beta-globin locus) responsible for sickle cell disease. This advanced genetic analysis employs polymerase chain reaction (PCR) amplification followed by Sanger DNA sequencing to detect the hallmark c.20A>T (p.Glu7Val) mutation, as well as compound heterozygous states including HbC, HbD-Punjab, HbO-Arab, and rare beta-thalassemia interactions that modulate clinical severity. For UAE patients, where consanguinity rates and hemoglobinopathy carrier frequencies remain significant public health priorities, this test delivers unambiguous genotype confirmation essential for prenatal counseling, premarital screening compliance, and personalized disease management planning.

Feature Our Sickle Cell Mutation Detection Test Standard Hemoglobin Electrophoresis
Diagnostic Precision 99.9% sensitivity; detects point mutations, compound heterozygosity, and silent carrier states at nucleotide resolution Limited to protein-level detection; misses silent carriers and cannot distinguish HbS from rare co-migrating variants
Methodology PCR Amplification + Sanger DNA Sequencing (Gold Standard), validated per ISO 9001:2015 Alkaline and Acid Hemoglobin Electrophoresis; semi-quantitative
Turnaround Time Sample Mon by 11 AM → Report Friday (5 business days) Typically 3–7 business days; may require reflex to molecular testing for ambiguous results
Clinical Utility Definitive genotype for prenatal diagnosis, premarital genetic counseling, and eligibility assessment for disease-modifying therapies Screening only; requires molecular confirmation for diagnostic certainty

Physician Insight & Safety Protocols

Clinical Correlation Note — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

As a consultant medical geneticist managing hereditary hemoglobinopathies across the UAE's diverse population, I emphasize that a positive mutation detection result must always be interpreted alongside complete blood count indices, reticulocyte count, and iron studies. A negative result for the common HbS mutation does not exclude rare hemoglobinopathies or atypical beta-globin variants. The molecular report provides the definitive genotype needed for reproductive risk counseling and therapeutic planning, but all treatment decisions — including hydroxyurea initiation, transfusion protocols, and eligibility for gene therapy trials — must be made collaboratively with your hematologist.

Medication Advisory

Important Medication Safety Notice

Do not discontinue any prescribed medication — including hydroxyurea, L-glutamine, voxelotor, crizanlizumab, or opioid analgesics — without consulting your treating physician. Abrupt cessation may precipitate vaso-occlusive crisis, acute chest syndrome, or severe rebound pain episodes. The molecular test result does not replace ongoing clinical management or medication adjustments supervised by your specialist.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria — Do Not Proceed with Home Collection If

  • Patient is currently experiencing acute vaso-occlusive crisis with severe pain (pain score ≥7/10)
  • Active fever ≥38.5°C with clinical suspicion of acute chest syndrome or splenic sequestration
  • Hemoglobin level below 5.0 g/dL on most recent assessment (within 72 hours)
  • Patient has received packed red blood cell transfusion within the preceding 90 days (may confound molecular testing via donor DNA interference in peripheral blood)
  • Current hospitalization in intensive care setting

Emergency Red Flags — Proceed Directly to Emergency Department

  • Sudden onset dyspnea, tachypnea, or oxygen saturation below 92% on room air
  • Acute neurological deficit: confusion, seizure, focal weakness, or visual disturbance
  • Priapism lasting more than 4 hours (urological emergency)
  • Severe pallor with lethargy and hemodynamic instability (suggestive of aplastic crisis or splenic sequestration)
  • Temperature exceeding 39°C with rigors in a patient with sickle cell disease (presumptive sepsis until proven otherwise)

Patient FAQ & Clinical Guidance

1. What does the Sickle Cell Anemia Mutation Detection Test diagnose and how is it different from a routine hemoglobin electrophoresis test?

This molecular genetic test directly identifies the specific DNA mutation in the HBB gene that causes sickle cell anemia by analyzing the nucleotide sequence, providing definitive genotype confirmation that hemoglobin electrophoresis cannot achieve because electrophoresis only measures protein quantities and cannot detect silent carrier states, compound heterozygous conditions, or rare variants that co-migrate with normal hemoglobin fractions on gel-based assays.

2. My partner and I are both asymptomatic — why would we need this test before marriage in the UAE?

Asymptomatic sickle cell trait carriers possess one normal HBB allele and one mutated allele, meaning they are clinically silent but have a 25% risk of having a child with full sickle cell disease if both partners carry the trait, which is precisely why the UAE Premarital Screening Program mandates hemoglobinopathy genetic testing to empower couples with actionable reproductive risk information, carrier detection, and access to prenatal diagnostic options before conception or during early pregnancy.

3. How long does it take to receive results and what post-test support is provided?

Full genetic analysis results are issued within five business days from sample receipt (sample delivered Monday before 11 AM yields results on Friday). Every test includes a complimentary post-result telephonic consultation with a specialist to explain the genetic report in plain language, discuss reproductive implications if applicable, and provide referrals to hematology or genetic counseling services as needed.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance & Data Protection Framework

This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) governing the processing of genomic and health data, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields which establishes standards for electronic health records and telemedicine. Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All molecular testing is performed at DNA Labs UAE, DHA-licensed Facility 1143, under ISO 9001:2015 quality management standards. Genomic data is encrypted, access-controlled, and never shared with third parties without explicit patient consent.

Clinical & Logistical Metadata

Test Name Sickle Cell Anemia Mutation Detection Test (HBB Gene Sequencing)
Price (AED) 800 AED
Turnaround Time 5 business days (sample Mon by 11 AM → report Friday)
Sample Type / Matrix Whole blood (4 mL, minimum 2 mL) — Lavender Top EDTA tube; transport at 2–8°C; DO NOT FREEZE
Methodology Used PCR Amplification + Sanger DNA Sequencing (Gold Standard)
ICD-10-CM Code D57.1, D57.3
LOINC Code 34565-2
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians